About pegasparg ase
Pegylated asparagine-specific enzyme
Used for
- Used with other chemotherapy medicines to treat acute lymphoblastic leukaemia (ALL).
Usual adult dose
Usually 2,000 IU/m² intravenously or intramuscularly every 14 days; regimen-dependent.
Usual dose in children
Usually 2,500 IU/m² intravenously or intramuscularly every 14 days; regimen-dependent.
Common side effects
- Allergic reactions, including severe anaphylaxis
- Pancreatitis
- Blood clots or bleeding
- Liver problems, nausea, or high blood sugar
Important warnings
- Can cause life-threatening allergic reactions; supervised administration is required.
- May cause pancreatitis, serious liver injury, clotting problems, or bleeding.
- Monitor blood counts, liver tests, glucose, and clotting during treatment.
- Avoid or use only under specialist direction with prior severe allergy or pancreatitis.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for at least three months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least three months after the last dose.
Interactions
- Vincristine may increase toxicity, including nerve and liver effects.
- Methotrexate or cytarabine effects may be altered by treatment timing.
- May reduce effectiveness of oral contraceptives; use additional contraception.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.